Our analysis showed significantly increased percentages of CD3+, CD4+/CD8+, CD3−CD56+, CD3+CD56+ and CD16+CD56+ T cells upon CIK/DC-CIK treatment, indicating that immune function of CRC patients was improved after CIK/DC-CIK immunotherapy [56, 57]. This evidence concerns the gene CD4 and colorectal carcinoma.